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Abstract In cystic fibrosis (CF) lung disease, exhaled
nitric oxide (FeNO) is not raised, but rather is normal or
even decreased when measured at a single expiratory flow.
FeNO measurements at several flow rates allow differen-
tiation between alveolar and bronchial nitric oxide (NO)
production. Extended FeNO measurements therefore
should be useful to localize the FeNO deficit in CF airways.
FeNO was measured in stable CF adults with moderate
lung disease and in healthy controls. Bronchial NO fluxes
(JNO,Br) and alveolar NO concentrations (CAlv) were cal-
culated from FeNO measurements at flow rates of 100, 150
and 200 ml/s using a method previously described. Thirty-
two adults were included in the study, 12 of whom had CF.
CF adults had significantly lower FeNO values at all flow
rates. The median JNO,Br was significantly lower in CF
adults than in healthy controls [0.31 nl/s (range = 0.11–
0.63) vs. 0.70 nl/s (0.27–3.52); P \ 0.001], while the
median CAlv was similar in both groups [1.7 ppb (0.3–3.9)
vs. 1.2 (0.1–5.2)]. Pulmonary NO exchange did not differ
significantly between subgroups of CF patients with and
without chronic Pseudomonas aeruginosa infection. No
significant correlation was detectable between FEV1/VC
and JNO,Br and CAlv, respectively. Extended FeNO mea-
surements can separate alveolar and bronchial NO outputs
in CF adults. The lower FeNO in adults with moderate to
severe CF lung disease is likely to be the result of lower
bronchial NO output.
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Introduction
Nitric oxide (NO), an important signalling mediator in
many organ systems, is synthesized from L-arginine by
nitric oxide synthetase (NOS), which exists in two consti-
tutive (cNOS) and one inducible (iNOS) isoform. The
constitutive isoforms are localized in airway nerves and in
bronchial epithelium, in type II alveolar epithelial cells,
and in endothelial cells of pulmonary blood vessels, where
they synthesize low amounts of NO for regulatory purposes
[1]. On the other hand, iNOS releases large quantities of
NO on induction by proinflammatory cytokines. Inducible
NOS immunoreactivity has been shown in many cell types
such as neutrophils, eosinophils, macrophages, type II
alveolar epithelial cells, airway epithelial cells, mast cells,
fibroblasts, endothelial cells, and airway and vascular
smooth muscle cells [2]. Thus, it is not surprising that NO
serves diverse physiological and cellular functions in the
lungs. The measurement of fractional NO concentrations in
exhaled air (FeNO) has been utilized to monitor various
conditions of the respiratory tract in health and disease
[2–4]. In inflammatory lung disease such as asthma, FeNO
has been found to be a useful noninvasive surrogate marker
of airway inflammation [5, 6].
In cystic fibrosis (CF) airways disease, characterized by
neutrophilic airway inflammation and chronic airway
infection, nasal and lower-airway FeNO is not raised, but
rather is normal or even decreased when measured at a single
expiratory flow [7–10]. Unfortunately, the use of constant
flow exercises does not allow differentiation if the endoge-
nous NO production originates in the proximal or peripheral
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airways of the lungs. A two-compartment model was
developed in the 1990s to interpret FeNO measurements
with regard to the regional distribution of endogenous NO
production [11–14]. According to this paradigm, FeNO is
the sum of two contributions, namely, the net NO output of
the airways, which are modeled as rigid tubes, and of the
alveolar compartment, which is modeled as a flexible bal-
loon [15–17]. The clinical applications of the two-com-
partment model are quite new. Based on the method of
Tsoukias and George [11], Suri et al. [18] have recently
found that alveolar, but not bronchial, NO production is
elevated in a cohort of CF children with mild lung disease.
To our knowledge, the pulmonary NO exchange
dynamics in CF adult patients have not been studied in detail
so far using the two-compartment model. Our study aimed to
analyze the flow-independent parameters of pulmonary NO
exchange in CF adults compared to healthy controls by
exploring the origin of the low FeNO previously observed in
CF airways.
Patients and Methods
Study Patients and Control Subjects
Adult CF patients were recruited from the Adult CF Unit of
the University Hospital Zurich, Switzerland. The diagnosis
of CF was based on standard criteria, including each
patient’s CF genotype. Patients were evaluated only if they
were clinically stable and without clinical signs of acute
infection exacerbation and had stable lung function at the
time of measurement. Chronic Pseudomonas aeruginosa
infection was defined according to a recently published
consensus definition, i.e., at least three positive sputum or
cough swab cultures over 6 months or more with a minimum
1-month interval in between [19]. All CF patients with
chronic Pseudomonas aeruginosa infection received main-
tenance treatment with oral azithromycin (500 mg three
times weekly) and long-term inhalation therapy with colistin
(1 million units twice daily) or TOBI (300 mg twice daily).
A subgroup of patients also were treated long-term with
nebulized dornase a daily. No CF patient received oral or
nebulized steroid treatment for at least 1 month prior to
the time of assessment. None of the CF patients had a
positive medical history of atopy. Skin prick tests were not
performed.
Healthy control subjects recruited for the purpose of the
study had no medical history of chronic illnesses, lung
disease, and/or atopy and no respiratory tract infection at
the time of their lung function measurements. No skin
prick tests were performed in control subjects. In addition,
control subjects had lung function test results [spirometry,
body plethysmograph, carbon monoxide (CO) diffusion
capacity] within normal limits. Smokers were excluded
from the study.
The Ethics Committee of the University Hospital Zurich
approved the study. Written informed consent was obtained
from all CF patients and healthy control subjects.
Measurement of Exhaled Nitric Oxide and Pulmonary
Function Test
FeNO was measured according to the guidelines of the
American Thoracic Society (ATS) and European Respira-
tory Society (ERS) with a CLD 88-NO analyzer (Eco
MedicsTM, Du¨rnten, Switzerland), using the chemilumi-
nescent NO measuring method [3]. The analyzer was cal-
ibrated daily and readjusted before each measurement.
Each subject inhaled NO-free air to total lung capacity and
exhaled as long as possible at four different exhalation flow
rates (VE = 50, 100, 150, and 200 ml/s) against a resis-
tance of 10 cm H2O L
-1 s-1. The breathing maneuvers
were repeated three times at each exhalation flow rate. The
different exhalation flow rates were obtained by using four
flow restrictors designed to produce a laminar flow of the
desired exhalation flow rate at a constant resistance of
10 cm H2O L
-1 s-1 for velum closure and normal
breathing pressure. The exhalation flow rate was measured
with an ultrasound flowmeter (Eco Medics), and biofeed-
back on a computer screen was used to maintain the desired
flow. The exhaled NO concentration (FeNO) was regis-
tered as a function of exhaled volume (Fig. 1a), while the
corresponding NO elimination rate VNO, the product of the
measured exhalation flow rate (VE) and the exhaled NO
concentration (FeNO), was recorded as a function of time
(Fig. 1b). The dead space of the flowmeter was 20 ml. The
end-expiratory FeNO (75–95% of the exhalation cycle) or
the corresponding VNO, respectively, was utilized for cal-
culations. Spirometry [forced expiratory volume in 1 s
(FEV1); forced vital capacity (FVC)] was performed on the
same day before NO measurements. Pulmonary function
tests were performed according to our laboratory protocols,
which are based upon adult European Respiratory Society
(ERS) standard testing [20, 21].
Calculation of Alveolar NO Concentration (CAlv)
and Bronchial NO flux (JNO,Br)
The alveolar NO concentration (CAlv) and the bronchial
NO flux (JNO,Br) were calculated according to the model of
Tsoukias and George [11] and as described in detail by
Lehtimaki et al. [14, 15]. In the two-compartment model
the end-expiratory FeNO at VE C 100 ml/s originates
mainly from the lower respiratory tract. Therefore, in the
end-expiratory phase and at VE C 100 ml/s, the NO
elimination rate VNO is a linear function of the exhalation
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flow rate VE, with the slope representing the alveolar NO
concentration (CAlv) and a nonzero intercept approximating
the bronchial NO flux (JNO,Br). In Fig. 1c we show
regression lines calculated from data of a healthy control
and a CF patient. Although we also measured FeNO at
VE = 50 ml/s, as recommended by the ATS and ERS
guidelines, only VNO values obtained at VE C 100 ml/s
were used for the calculation.
Fig. 1 Measurement of end-expiratory FeNO and calculation of flow-
independent parameters. Examples of online measurements at
VE = 50 ml/s in rows A (FeNO vs. volume) and B (VNO vs. time)
for a healthy control and a CF patient show that a plateau phase is
established which allows extraction of end-expiratory FeNO according
to the ATS and ERS guidelines. In row C the linear relationship
between VNO and VE at VE C 100 ml/s is demonstrated and allows
determination of the flow-independent parameters CAlv (slope) and
JNO,Br (intercept) according to Refs. [11] and [14]
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Statistics
Values are expressed as mean and 95% CI (confidence
interval) of the mean, and, where appropriate, the median
and range are presented for skewed data. The Mann–
Whitney test was used for statistical calculation. P \ 0.05
was considered statistically significant. Correlations
between bronchial obstruction (FEV1/VC) and CAlv and
JNO,Br were made using Spearman’s rank test.
Results
Twelve adult CF patients and 20 healthy control subjects
were included in the study. Patient demographics are given
in Table 1. Age and gender distribution were similar in the
two groups. All except of one patient were DF508 homo-
zygous. Patients had moderate to severe CF lung disease
(median FEV1 = 1.6 L or 48% predicted), and two-thirds
were chronically infected with Pseudomonas aeruginosa.
At the time of recruitment, none of the CF patients was
listed for lung transplantation, even though the patients’
mean age was greater than 30 years, which is higher than
the mean age of 26.2 years for CF patients transplanted at
our center in the last decade [22].
As described above, the end-expiratory FeNO (75-95%
of the exhalation cycle) at an exhalation flow rate of
VE C 100 ml/s was utilized for calculations. The mean
standard deviations of end-expiratory FeNO were
0.7 ± 0.4, 0.4 ± 0.3, 0.3 ± 0.2, and 0.3 ± 0.1 ppb for the
flow rates of 50, 100, 150, and 200 ml/s, respectively. In
CF patients, end-expiratory FeNO was significantly lower
compared to that of healthy control subjects at all exhala-
tion flow rates (Fig. 2). There was a negative linear cor-
relation between end-expiratory FeNO and exhalation flow
rates VE C 100 ml/s observed in both the CF patient group
and the control groups (Figs. 1 and 2). Thus, the analytical
tools of the two-compartment model can be applied to our
data.
Significantly lower bronchial NO fluxes (JNO,Br) were
documented in CF adults compared to healthy controls,
while alveolar NO concentrations (CAlv) were similar in
both groups, as displayed in Fig. 3. Similarly, CAlv and
JNO,Br did not differ significantly between subgroups of CF
patients with and without chronic Pseudomonas aerugin-
osa infection (Fig. 3), as well as between CF patients with
and without dornase a inhalation, even though the number
Table 1 Demographics of study population
Healthy
controls
Cystic fibrosis
adults
N 20 12
Gender (female/male) 11/9 5/7
Age (range) (years) 27.4 (18.5–46.7) 24.2 (22.8–55.3)
FEV1 (L)* 3.7 (3.2–5.5) 1.6 (0.9–3.6)
FEV1 (% predicted)* 97 (83–118) 48 (26–89)
Chronic Pseudomonas
aeruginosa infection
Not applicable 8
Nebulized dornase
a long-term therapy
Not applicable 5
CAlv = alveolar NO concentration; JNO,Br = bronchial nitric oxide
flux; FEV1 = forced expiratory volume in 1 s
Values are expressed as median (range)
* Mann–Whitney test P \ 0.0001
Fig. 2 End-expiratory FeNO at different fixed exhalation flow rates.
The average end-expiratory FeNO from three consecutive measure-
ments at each of four fixed exhalation flow rates (VE = 50, 100, 150,
and 200 ml/s) is shown for each healthy control (d) and each CF
patient (s). The mean FeNO of each group is depicted as a line.
Significant (P \ 0.05) P values as calculated using the Mann–
Whitney test are given above the groups compared
Fig. 3 Comparison of alveolar NO concentration (CAlv) and bron-
chial NO flux (JNO,Br) of healthy controls and CF patients. Alveolar
NO concentrations (a) and bronchial NO fluxes (b) as calculated from
the data presented in Fig. 2 are shown for each healthy control (d)
and each CF patient without (s) and with (m) chronic Pseudomonas
aeruginosa infection. The mean value of each group is depicted as a
line. Significant (P \ 0.05) P values as calculated using the Mann–
Whitney test are given above the groups compared
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of patients in each subgroup was small [alveolar NO con-
centration: 1.8 ppb (95 CI = 0.8–2.8 ppb) vs. 1.9 ppb (95
CI = 0.7–3.1 ppb); bronchial NO flux: 0.426 nl/s (95
CI = 0.175–0.676 nl/s) vs. 0.229 nl/s (95 CI = 0.117–
0.340 nl/s)].
Data of flow dependency of FeNO in CF patients and
healthy control subjects are given in Fig. 4. No significant
correlation was detectable between bronchial obstruction
(FEV1/VC) and the two independent NO exchange param-
eters CAlv and JNO, Br. Therefore, and after having proven the
applicability of the two-compartment model to our data
(Figs. 1 and 2), calculated CAlv and JNO, Br values represent
true parameters of NO exchange in the study patients and
healthy controls.
Discussion
This study assessed flow-independent parameters of pul-
monary NO exchange—the bronchial NO flux JNO,Br and
the alveolar NO concentration CAlv—in CF adults and
healthy controls. Our data show that bronchial NO flux is
lowered in adults with moderate CF lung disease. Fur-
thermore, alveolar NO concentrations in healthy controls
and CF adults were found to be similar. Moreover, no
correlation was detected between bronchial airway
obstruction and alveolar or bronchial NO in CF adults.
Nitric oxide is an important signalling mediator and is
involved in multiple physiological and cellular functions in
the lungs. Therefore, measurements of NO concentration in
exhaled air have been utilized extensively for various air-
way diseases, in particular, asthma but also CF [1]. Mea-
surements of FeNO have been performed successfully in
infants, children, and adults. In CF, a common inherited
disease in Caucasians, chronic neutrophilic inflammation
of the lungs and chronic airway infection cause progressive
lung disease, the leading cause of morbidity and mortality
in CF patients [23]. However, despite the chronic inflam-
matory character of CF airways disease, FeNo has been
shown to be rather normal or even decreased [8–10]. The
suspected causes of decreased FeNO in CF are numerous
and can be summarized as follows: (1) decreased NO
production secondary to impaired iNOS expression/activity
or L-arginine deficiency [24–29], (2) increased bacterial,
enzymatic, or chemical NO consumption [4, 30–33], and
(3) slower NO diffusion through the highly viscous and
abundant mucus of CF patients [24, 34].
We found similar JNO,Br estimates for our CF patients
with and without chronic Pseudomonas aeruginosa infec-
tion; therefore, NO consumption by resident bacterial
pathogens or microbial enzymes seems unlikely the major
cause for low bronchial NO output. In contrast, there was a
trend toward higher bronchial NO flux in the subgroup of CF
patients with dornase a treatment compared with those
without dornase a treatment, most likely not statistically
significant due to the small number of patients in this sub-
group. High mucus viscosity presumably lowering NO dif-
fusion rate and increasing net NO consumption during its
passage through the mucus could thus be accountable for the
low NO output in CF adults. In a recent placebo-controlled
study, Grasemann et al. [35] showed that FeNO positively
correlates with nebulized dornase a treatment in CF chil-
dren. Nevertheless, based on our results and published evi-
dence to date, it cannot be ruled out that impaired NO
production also contributes to or even represents the major
source of the measured deficit of exhaled NO in CF patients.
Fig. 4 Correlation between
alveolar NO concentration
(CAlv) or bronchial NO flux
(JNO,Br) and airway obstruction
(FEV/VC). The alveolar NO
concentrations (a, b) and the
bronchial NO fluxes (c, d) of
healthy controls (d) and CF
patients (s) were plotted
against their corresponding
airway obstruction as measured
by spirometry immediately
before FeNO measurements.
Correlation was tested using
Spearman’s rank test
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Flow-independent parameters of NO exchange have
recently been explored. Shin et al. [36] used a single-breath
technique that showed similar bronchial NO fluxes (JNO,Br)
but lower alveolar NO concentrations (Calv) in CF children
compared with healthy controls; however, the increase of
mean NO was only weakly significant (P = 0.05), with a
high standard deviation for CF patients and healthy con-
trols. Suri et al. [18], using extended NO exchange mea-
surements similar to the methods used in our study,
reported that JNO,Br did not differ between healthy children
and CF children while Calv was higher in the patient group.
The different results of the studies by Shin et al. and Suri
et al. with respect to Calv are likely due to the different
experimental protocols and parameter estimation methods
employed, since both studies enrolled patients of similar
mean age (12 vs. 13.3 years) and mild CF lung disease
(mean FEV1/FVC ratios of 81 vs. 82). Our CF adult study
cohort had a mean age of 30.3 years, more frequently
chronic Pseudomonas aeruginosa infection, and moderate
to severe lung disease. It remains to be proven if the degree
of airway obstruction could explain the lowered bronchial
NO fluxes in CF adults compared to the results of Shin
et al. and Suri et al. Consequently, age-related features and
the progression of CF lung disease might likely influence
the bronchial NO flux in CF patients.
Suri et al. [18] reported that children with severe lung
disease (FEV1 \ 40%) were not able to perform exhalation
maneuvers at highest flows. In contrast, our adult study
patients with advanced CF lung disease experienced no
particular problems using the same technique at higher
flows. Adult age might be one of the reasons for this
observation.
In our study, three-fourths of the CF patients were
chronically infected with Pseudomonas aeruginosa and
therefore treated long-term with oral azithromycin
according to our center’s policy. Azithromycin, a macro-
lide antibiotic, has frequently been used in recent years as
an immunomodulatory agent in advanced CF lung disease,
even though its mechanism of action remains unclear [37].
In our study, however, pulmonary NO exchange dynamics
in CF adults with and without azithromycin therapy seem
not to differ significantly; however, the patient numbers of
each subgroup were too small to determine the impact of
chronic airway infection and long-term azithromycin
therapy reliably.
Our study has limitations which are part of its cross-
sectional design and the small study cohort. Nevertheless,
we were able to assess pulmonary NO exchange dynamics in
CF adults, showing that CF patients without acute exacer-
bation have lower FeNO values compared to healthy con-
trols as measured at exhalation flow rates of 50–200 ml/s.
Alveolar NO concentrations are similar in CF and healthy
adults, and the difference of FeNO is likely to be the result of
lower bronchial NO flux. Because NO output is the sum of
NO that originates from alveolar and bronchial compart-
ments, our findings might explain the overall low values of
FeNO in CF patients, probably influenced by multiple fac-
tors, including viscous mucus as a diffusion barrier for air-
way NO, NO consumption by bacterial enzymes, and
decreased NO production.
Interestingly, four healthy controls in our study who did
not have signs of atopy, asthma, or allergic rhinitis had
high FeNO50 (C30 ppb). However, even with their exclu-
sion from the analysis, results remained similar and sta-
tistically significant.
The major goal of our study was a proof of principle,
that is, the validity of the methodology proposed by
Tsoukias and George to assess alveolar and bronchial
contributions to exhaled NO in CF adults. The described
method using three additional flow rates of 100, 150, and
200 ml/s can be performed easily and allows the calcula-
tion of alveolar NO concentration (CAlv) and bronchial NO
flux (JNO,Br) with a simple linear regression equation.
Further work is needed to fully understand pulmonary
NO exchange dynamics in the different stages of CF lung
disease across different age groups and in larger cohorts,
but also compared to other chronic lung diseases such as
non-CF bronchiectasis.
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